Evaluation of the Impact of Psychomotricity on the Patients Body Experience in Palliative Care (PSYCHOMOTPAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03959813|
Recruitment Status : Not yet recruiting
First Posted : May 22, 2019
Last Update Posted : May 22, 2019
Palliative care is part of a comprehensive approach to the person, in the advanced phase of a serious illness. The purpose of this care is to relieve painful symptoms, to promote comfort and quality of life. In the context of a serious illness, the sick person is confronted with body modifications that have an impact on his body experience, that is, on his feelings and on the image that he has of his body.
Psychomotricity is a paramedical discipline that focuses on body-psyche links. The psychomotor therapist is authorized to take care of psychomotor disorders, as defined in the decree of competences. These psychomotor disorders appear in connection with the evolution of the serious illness and the presence of symptoms in these patients (ex: disorders of the tonic regulation, psychomotor disharmony, disorders of the representation of the body, etc.). In palliative care, the psychomotor therapist seeks to regulate these psychomotor disorders and thus to promote a more satisfying physical experience in the patient, through the use of different bodily approaches.
Several studies have shown the beneficial effects of touching and moving the body in cancer patients, but no work evaluating the effects of the psychomotor approach (involving various body mediations) on the body experience of patients with cancer in palliative situation
|Condition or disease||Intervention/treatment|
|Palliative Care||Other: Psychomotricity by touching and passive mobilizations|
|Study Type :||Observational|
|Estimated Enrollment :||38 participants|
|Official Title:||Evaluation of the Impact of Psychomotricity on the Patients Body Experience in Palliative Care|
|Estimated Study Start Date :||September 1, 2019|
|Estimated Primary Completion Date :||November 1, 2021|
|Estimated Study Completion Date :||November 1, 2021|
- Other: Psychomotricity by touching and passive mobilizations
The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.
Before and after the session, two evaluations will be offered to the patient and performed by a nurse:
- A questionnaire, based on the physical experience,
- The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.
A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity.
- Realization of a questionnaire, based on the patient's global and physical feeling [ Time Frame: 30 minutes before psychomotor care ]questionnaire used to assess the impact of psychomotor care on the body experience of patients with advanced palliative care cancer, in both a physical and psychological dimension
- Realization of a questionnaire, based on the patient's global and physical feeling [ Time Frame: 30 minutes after psychomotor care ]questionnaire used to assess the impact of psychomotor care on the body experience of patients with advanced palliative care cancer, in both a physical and psychological dimension
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03959813
|Contact: Marion Rousseauemail@example.com|